DOP2014000200A - Compuestos inhibidores de raf - Google Patents

Compuestos inhibidores de raf

Info

Publication number
DOP2014000200A
DOP2014000200A DO2014000200A DO2014000200A DOP2014000200A DO P2014000200 A DOP2014000200 A DO P2014000200A DO 2014000200 A DO2014000200 A DO 2014000200A DO 2014000200 A DO2014000200 A DO 2014000200A DO P2014000200 A DOP2014000200 A DO P2014000200A
Authority
DO
Dominican Republic
Prior art keywords
inhibiting compounds
raf
raf inhibiting
pyrido
cancer
Prior art date
Application number
DO2014000200A
Other languages
English (en)
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael D Kaufman
Phenil J Patel
Craig D Wolfangel
Original Assignee
Lilly Co Eli
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Deciphera Pharmaceuticals Llc filed Critical Lilly Co Eli
Publication of DOP2014000200A publication Critical patent/DOP2014000200A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Abstract

La presente invención se refiere a un compuesto pirido[2,3-d]pirimidina, o una sal del mismo farmacéuticamente aceptable, que inhibe a Raf y, por lo tanto, puede ser útil en el tratamiento de cáncer.
DO2014000200A 2012-03-07 2014-09-04 Compuestos inhibidores de raf DOP2014000200A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
DOP2014000200A true DOP2014000200A (es) 2014-10-15

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000200A DOP2014000200A (es) 2012-03-07 2014-09-04 Compuestos inhibidores de raf

Country Status (39)

Country Link
US (2) US9334267B2 (es)
EP (1) EP2850082B1 (es)
JP (1) JP2015509536A (es)
KR (1) KR20140129087A (es)
CN (1) CN104302646B (es)
AP (1) AP2014007899A0 (es)
AR (1) AR090151A1 (es)
AU (1) AU2013230146B2 (es)
BR (1) BR112014018528A8 (es)
CA (1) CA2863673A1 (es)
CL (1) CL2014002220A1 (es)
CO (1) CO7010837A2 (es)
CR (1) CR20140378A (es)
CY (1) CY1117846T1 (es)
DK (1) DK2850082T3 (es)
DO (1) DOP2014000200A (es)
EA (1) EA024824B1 (es)
EC (1) ECSP14017584A (es)
ES (1) ES2584387T3 (es)
HK (1) HK1202541A1 (es)
HR (1) HRP20160654T1 (es)
HU (1) HUE028095T2 (es)
IL (1) IL234052A (es)
IN (1) IN2014MN01575A (es)
LT (1) LT2850082T (es)
MA (1) MA37316B1 (es)
ME (1) ME02423B (es)
MX (1) MX2014010701A (es)
NZ (1) NZ627454A (es)
PE (1) PE20142338A1 (es)
PH (1) PH12014501986A1 (es)
PT (1) PT2850082T (es)
RS (1) RS54840B1 (es)
SG (1) SG11201404969YA (es)
SI (1) SI2850082T1 (es)
TN (1) TN2014000375A1 (es)
TW (1) TW201348233A (es)
UA (1) UA112340C2 (es)
WO (2) WO2013134243A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
US20190175609A1 (en) * 2016-06-10 2019-06-13 Novartis Ag Therapeutic uses of a c-raf inhibitor
CN110167928A (zh) 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
TW201902517A (zh) * 2017-04-28 2019-01-16 美商石英醫療公司 Ｒａｆ降解結合物化合物
HUE062076T2 (hu) 2017-12-21 2023-09-28 Boehringer Ingelheim Int Benzilamino-szubsztituált piridopirimidinonok és származékai mint sos1
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
PL3902547T3 (pl) 2018-12-28 2024-02-26 Deciphera Pharmaceuticals, Llc Inhibitory CSF1R do stosowania w leczeniu nowotworu złośliwego
RS65040B1 (sr) 2019-02-06 2024-02-29 Lilly Co Eli Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)uree kao kcnq potencijatori
CA3138300A1 (en) * 2019-05-03 2020-11-12 Kinnate Biopharma Inc. Inhibitors of raf kinases
JP2022531932A (ja) 2019-05-10 2022-07-12 デシフェラ・ファーマシューティカルズ，エルエルシー ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
US11530206B2 (en) 2019-05-10 2022-12-20 Deciphera Pharmaceuticals, Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
EP4326256A1 (en) 2021-04-23 2024-02-28 Kinnate Biopharma Inc. Treatment of cancer with a raf inhibitor
US20220388986A1 (en) 2021-04-29 2022-12-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202342442A (zh) 2021-12-09 2023-11-01 美商迪賽孚爾製藥有限公司 Ｒａｆ激酶抑制劑及其使用方法
WO2023118250A1 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US8901137B2 (en) * 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
AU2013230146A1 (en) 2014-08-14
EA024824B1 (ru) 2016-10-31
RS54840B1 (sr) 2016-10-31
EP2850082A1 (en) 2015-03-25
SG11201404969YA (en) 2014-10-30
US8741911B2 (en) 2014-06-03
IL234052A (en) 2016-05-31
CL2014002220A1 (es) 2015-06-05
TW201348233A (zh) 2013-12-01
CN104302646A (zh) 2015-01-21
JP2015509536A (ja) 2015-03-30
PH12014501986B1 (en) 2014-11-24
ES2584387T3 (es) 2016-09-27
CY1117846T1 (el) 2017-05-17
LT2850082T (lt) 2016-09-12
AP2014007899A0 (en) 2014-08-31
CR20140378A (es) 2014-11-27
PE20142338A1 (es) 2015-01-10
US9334267B2 (en) 2016-05-10
CA2863673A1 (en) 2013-09-12
HK1202541A1 (en) 2015-10-02
MA37316B1 (fr) 2017-03-31
AR090151A1 (es) 2014-10-22
CO7010837A2 (es) 2014-07-31
SI2850082T1 (sl) 2016-07-29
BR112014018528A2 (es) 2017-06-20
MX2014010701A (es) 2015-03-10
ME02423B (me) 2016-09-20
AU2013230146B2 (en) 2015-09-10
US20150119392A1 (en) 2015-04-30
WO2013134252A1 (en) 2013-09-12
ECSP14017584A (es) 2016-01-29
US20130252977A1 (en) 2013-09-26
BR112014018528A8 (pt) 2017-07-11
PH12014501986A1 (en) 2014-11-24
IN2014MN01575A (es) 2015-05-08
UA112340C2 (uk) 2016-08-25
HUE028095T2 (en) 2016-11-28
MA37316A1 (fr) 2016-06-30
NZ627454A (en) 2016-09-30
DK2850082T3 (en) 2016-08-15
EP2850082B1 (en) 2016-05-18
KR20140129087A (ko) 2014-11-06
TN2014000375A1 (en) 2015-12-21
PT2850082T (pt) 2016-07-15
HRP20160654T1 (hr) 2016-07-01
EA201491456A1 (ru) 2014-12-30
CN104302646B (zh) 2016-05-04
WO2013134243A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
DOP2014000200A (es) Compuestos inhibidores de raf
CR20150416A (es) Inhibidores de cdc7
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
ECSP13012764A (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR
IN2015DN01156A (es)
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
MX364486B (es) Derivados de piridazinona-amidas.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
MX359664B (es) Tratamiento de cáncer de mama.
ECSP17029203A (es) Inhibidor de cinasa aurora a
PA8850801A1 (es) Compuestos útiles para inhibir chk1
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
UA115357C2 (uk) Похідні піридин-4-ілу
MX2015012741A (es) Palbociclib deuterado.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
SG10201900541QA (en) Derivatives of xanthone compounds
PE20170523A1 (es) Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
MX2015012386A (es) Inhibidores de la cinasa cdk9.
IN2014KN01772A (es)
CL2014001265A1 (es) Compuestos derivados de uracilo, inhibidores de la quinasa axl y c-met, utiles en el tratamiento del cancer.
TH159388A (th) สารประกอบแมคโครไซคลิคและวิธีการผลิตของมัน